JanOne (JAN)2025-03-31 16:38Financial Performance - ALT5 Sigma achieved record Q4 revenue of 12.53 million for its Fintech segment[4][12]. - The Fintech segment reported a strong annual gross margin of 50.2% and an impressive adjusted EBITDA of 18.2%[2][12]. - The Fintech segment's adjusted Q4 EBITDA was approximately 2 billion USD in cryptocurrency transactions in 2024[20]. Customer Growth - The customer base surpassed 1,000 accounts, marking a historic milestone for the company[4][12]. Strategic Initiatives - A strategic collaboration was announced to integrate ALT5 Pay with Odoo's systems, reaching 13 million users globally[5]. - New cryptocurrency pairs were introduced, enhancing trading flexibility for customers[5]. - ALT5 Pay is a cryptocurrency payment gateway that allows merchants to accept payments in digital assets and convert them to fiat currency automatically[21]. - ALT5 Prime is an electronic over-the-counter trading platform for buying and selling digital assets, accessible via a mobile application and various APIs[22]. Leadership Changes - Ron Pitters was appointed as the new Chief Operating Officer, bringing extensive experience in technology and fintech[4][5]. Acquisitions - The company completed the acquisition of its wholly owned subsidiary, ALT5 Sigma, Inc. in May 2024[5]. Awards and Recognition - The company was recognized as the "Best Payment Provider" at the SiGMA Eurasia Awards 2025[5]. Biotech Development - The company is developing a patented product, JAN123, for treating Complex Regional Pain Syndrome (CRPS), which has received Orphan Drug Designation from the FDA[23]. - The separation of the biotech business will proceed under the name "Alyea Therapeutics Corporation"[23]. Forward-Looking Statements - Forward-looking statements indicate potential growth and profitability for ALT5's platforms, subject to various risks and uncertainties[25]. - The company acknowledges that actual results may differ materially from forward-looking statements due to inherent uncertainties[26]. - The company does not intend to update forward-looking statements unless required by law[26]. - Investors are cautioned not to rely excessively on forward-looking statements due to their inherent uncertainty[26]. Contact Information - Media and investor relations can be contacted at IR@alt5sigma.com or 1-800-400-2247[27].